Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (7999)	11/11/2001 4:33:46 PM
From: Montana Wildhack	Read Replies (3) \| Respond to of 14101

Quite intersting overview of the European pharma market by the European Federation of Pharmaceutical Industries Association (EFPIA) Its in Acrobat Reader: efpia.org PH A R M A C E U T I C A L MA R K E T VA L U E (AT E X-FA C T O RY P R I C E S) EFPIA 1997 Euro million Austria 1,345 Belgium 2,197 Denmark 811 Finland 918 France 13,875 Germany 15,735 Greece 1,027 Ireland 479 Italy 8,908 Netherlands 1,908 Norway 649 Portugal 1,563 Spain 5,305 Sweden 1,676 Switzerland 1,532 Turkey 1,765 United Kingdom 7,881 Total 67,574 PAY M E N T F O R PH A R M A C E U T I C A L S B Y STAT U T O RY HE A LT H IN S U R A N C E SY S T E M S/ NAT I O N A L HE A LT H SE RV I C E S EFPIA 1997 Euro million Austria 1,217 Belgium 1,697 Denmark 653 Finland 559 France 14,122(*) Germany 16,313 Greece 1,545 Ireland 299 Italy 6,038 Netherlands 3,022 Norway 762 Portugal 786 Spain 5,738 Sweden 1,456 Switzerland 1,512 Turkey n.a. United Kingdom 7,881 Total 63,600 The members of this organization: ME M B E R CO M PA N I E S MEMBERS Akzo Nobel-Pharma Netherlands Almirall-Prodesfarma Spain Ares-Serono Switzerland Astra Sweden Baxter United States Bayer Germany Beaufour Ipsen France Boehringer Ingelheim Germany Bristol Myers Squibb United States Chiesi Farmaceutici Italy Eli Lilly & Co United States Laboratorios Esteve Spain Glaxo Wellcome United Kingdom Hoechst Marion Roussel Germany Johnson & Johnson United States Knoll Germany Leo Pharmaceutical Products Denmark H. Lundbeck Denmark Menarini Italy E. Merck Germany Merck & Co United States Novartis Switzerland Novo Nordisk Denmark Pfizer United States Pharmacia & Upjohn United States Rhône-Poulenc Pharma France Roche Switzerland Sanofi France Schering Germany Schering-Plough United States Searle United States Laboratoires Servier France Sigma-Tau Italy SmithKline Beecham United Kingdom Solvay Belgium Synthélabo France UCB Pharma Belgium Warner Lambert United States Wyeth-Ayerst (AHP) United States Zambon Group Italy Zeneca United Kingdom And one notable quote: By the time a medicinal product is placed on the market, an average of 10 to 12 years will have elapsed since the synthesis of the new active substance;